Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa
- PMID: 37623975
- PMCID: PMC10458554
- DOI: 10.3390/pathogens12081015
Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), remains a significant global health issue, with high morbidity and mortality rates. The emergence of drug-resistant strains, particularly multidrug-resistant TB (MDR-TB), poses difficult challenges to TB control efforts. This comprehensive review and meta-analysis investigated the prevalence of and molecular insights into isoniazid (INH) and rifampicin (RIF) resistance-conferring mutations in M. tb isolates from South Africa. Through systematic search and analysis of 11 relevant studies, we determined the prevalence of gene mutations associated with RIF and INH resistance, such as rpoB, katG, and inhA. The findings demonstrated a high prevalence of specific mutations, including S450L in rpoB, and S315T, which are linked to resistance against RIF and INH, respectively. These results contribute to the understanding of drug resistance mechanisms and provide valuable insights for the development of targeted interventions against drug-resistant TB.
Keywords: INH; RIF; drug resistance mechanisms; resistance-conferring mutations; tuberculosis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.S Afr Med J. 2019 Aug 28;109(9):659-664. doi: 10.7196/SAMJ.2019.v109i9.13730. S Afr Med J. 2019. PMID: 31635590
-
Drug resistant Mycobacterium tuberculosis in Oman: resistance-conferring mutations and lineage diversity.PeerJ. 2022 Jul 28;10:e13645. doi: 10.7717/peerj.13645. eCollection 2022. PeerJ. 2022. PMID: 35919400 Free PMC article.
-
Frequency of rpoB, katG, and inhA Gene Polymorphisms Associated with Multidrug-Resistant Mycobacterium tuberculosis Complex Isolates among Ethiopian TB Patients: A Systematic Review.Interdiscip Perspect Infect Dis. 2022 Jun 16;2022:1967675. doi: 10.1155/2022/1967675. eCollection 2022. Interdiscip Perspect Infect Dis. 2022. PMID: 35757683 Free PMC article.
-
Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2021 Feb 17;65(3):e02091-20. doi: 10.1128/AAC.02091-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33361298 Free PMC article.
-
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.Infect Genet Evol. 2016 Nov;45:474-492. doi: 10.1016/j.meegid.2016.09.004. Epub 2016 Sep 6. Infect Genet Evol. 2016. PMID: 27612406 Review.
Cited by
-
Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana.Front Microbiol. 2025 Feb 11;16:1535160. doi: 10.3389/fmicb.2025.1535160. eCollection 2025. Front Microbiol. 2025. PMID: 40008038 Free PMC article.
-
RpoB mutation patterns in Rifampicin-resistant tuberculosis: a Jiangxi Province study, 2021-2023.Sci Rep. 2025 Jul 31;15(1):27988. doi: 10.1038/s41598-025-11949-0. Sci Rep. 2025. PMID: 40745428 Free PMC article.
References
-
- World Health Organization (WHO) Global Tuberculosis Report 2020. WHO; Geneva, Switzerland: 2020. [(accessed on 16 April 2021)]. Available online: https://www.who.int/publications/i/item/9789240013131.
-
- World Health Organization (WHO) Global Tuberculosis Report 2019. WHO; Geneva, Switzerland: 2019. [(accessed on 16 April 2021)]. Available online: https://www.who.int/publications/i/item/9789241565714.
-
- Cox H., Goig G.A., Salaam-Dreyer Z., Dippenaar A., Reuter A., Mohr-Holland E., Daniels J., Cudahy P.G., Nicol M.P., Borrell S., et al. Whole-genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high-burden settings: A retrospective cohort study. J. Clin. Microbiol. 2022;60:e0236221. doi: 10.1128/jcm.02362-21. - DOI - PMC - PubMed
-
- Oostvogels S., Ley S.D., Heupink T.H., Dippenaar A., Streicher E.M., De Vos E., Meehan C.J., Dheda K., Warren R., Van Rie A. Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa. Microb. Genom. 2022;8:000815. doi: 10.1099/mgen.0.000815. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources